What is EVOFEM BIOSCIENCE INC's earnings per share (EPS)?

EVOFEM BIOSCIENCE INC (EVFM) reported diluted earnings per share of $0.00 for fiscal year 2025. This represents a 100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

EVOFEM BIOSCIENCE INC (EVFM) Financials

EVFM

Trailing 12 months to June 30, 2026

Revenue $18.0M +4.5% YoY

Net Income -$15.3M -145.3% YoY

EPS (Diluted) -$0.11 -120.0% YoY

Free Cash Flow -$477K YoY not available

Market Cap $1.0M as of Oct 9, 2026

Price / Sales 0.1x on $18.0M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EVFM SEC filings page.

EVOFEM BIOSCIENCE INC (EVFM) reported $18.0M in revenue over the twelve months to Jun 30, 2026, up 4.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI EVFM FY2025 2026-10-03

Profitability arrived through sharp cost reduction, but cash flow remains negative and the balance sheet is heavily liability-funded.

In FY2025, operating income turned positive at $3.4M while operating cash flow remained -$2.0M; the mismatch indicates earnings are not yet converting into cash. Receivables rose 26.9% while revenue grew 4.2%, making working capital—not capital spending—the likely cash drag.

The FY2024-to-FY2025 margin step-up came mainly from lower overhead: SG&A fell from $11.6M to $7.4M. Operating margin moved from -39.6% to 16.7% while gross margin narrowed, so the improvement reflects cost discipline more than demonstrated pricing power.

The balance sheet remains structurally strained: FY2025 liabilities were $94.6M against assets of $20.3M, leaving negative equity of $74.3M. A 0.2x current ratio and reported liquidity equal to 3.5 months of annual operating outflow indicate limited short-term coverage, while financing cash flow of $1.9M nearly offset the year's $2.0M operating cash outflow.

Financial Health Signals

Financial health score not available

EVOFEM BIOSCIENCE INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-64.53

EVOFEM BIOSCIENCE INC scores -64.53, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.0M) relative to total liabilities ($94.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

EVOFEM BIOSCIENCE INC passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

$5.09used

For every $1 of reported earnings, EVOFEM BIOSCIENCE INC used $5.09 of operating cash (-$2.0M OCF vs $391K net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage At Risk

1.43x

EVOFEM BIOSCIENCE INC earns $1.43 in operating income for every $1 of interest expense ($3.4M vs $2.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.6M

YoY-45.4%

QoQ+192.9%

5Y CAGR+7.2%

EVOFEM BIOSCIENCE INC generated $2.6M in revenue in Q2 2026. This represents a decrease of 45.4% from the same quarter a year earlier. Against the prior quarter it is up 192.9%.

EBITDA

-$2.5M

YoY-116.8%

QoQ+45.0%

EVOFEM BIOSCIENCE INC's EBITDA was -$2.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 116.8% from the same quarter a year earlier. Against the prior quarter it is up 45.0%.

Net Income

-$11.0M

YoY-518.6%

QoQ-101.9%

EVOFEM BIOSCIENCE INC reported -$11.0M in net income in Q2 2026. This represents a decrease of 518.6% from the same quarter a year earlier. Against the prior quarter it is down 101.9%.

EPS (Diluted)

-$0.08

YoY-700.0%

QoQ-100.0%

EVOFEM BIOSCIENCE INC earned -$0.08 per diluted share (EPS) in Q2 2026. This represents a decrease of 700.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Cash & Balance Sheet

Free Cash Flow

-$3.1M

QoQ-236.6%

EVOFEM BIOSCIENCE INC recorded an outflow of $3.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. Against the prior quarter it is down 236.6%.

Cash & Debt

$285K

YoY-61.9%

QoQ-80.9%

5Y CAGR-64.0%

10Y CAGR-35.1%

EVOFEM BIOSCIENCE INC held $285K in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

133M

YoY+11.7%

QoQ0.0%

5Y CAGR-3.1%

10Y CAGR+25.4%

EVOFEM BIOSCIENCE INC had 133M shares outstanding in Q2 2026. This represents an increase of 11.7% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

80.6%

YoY-3.8pp

QoQ+26.2pp

5Y change+25.8pp

EVOFEM BIOSCIENCE INC's gross margin was 80.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 3.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 26.2 percentage points.

Operating Margin

-94.5%

YoY-68.6pp

EVOFEM BIOSCIENCE INC's operating margin was -94.5% in Q2 2026, reflecting core business profitability. This is down 68.6 percentage points from the same quarter a year earlier.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

Capital Expenditures

QoQ-100.0%

EVOFEM BIOSCIENCE INC reported no capital expenditure in Q2 2026. Against the prior quarter it is down 100.0%.

R&D Spending

Not reported for Q2 2026.

Share Buybacks

Not reported for Q2 2026.

EVFM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EVFM quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	$18.0M	$20.2M+4.2%	$19.4M+6.3%	$18.2M+8.2%	$16.8M+104.2%	$8.2M+1748.4%	$446K	$0	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$4.4M	$4.6M+20.4%	$3.8M-41.1%	$6.5M+47.5%	$4.4M+8.9%	$4.1M+766.5%	$468K	$0	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$13.6M	$15.6M+0.2%	$15.5M+32.7%	$11.7M-5.8%	$12.4M+196.5%	$4.2M+19140.9%	-$22K	$0	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	$1.8M-37.2%	$2.9M-88.3%	$25.0M-24.4%	$33.1M+94.3%	$17.1M-23.3%	$22.2M	N/A	N/A	$14.9M-56.8%	$34.4M+564.9%	$5.2M-54.8%	$11.4M
SG&A Expenses	$7.4M	$7.4M-36.1%	$11.6M-22.6%	$14.9M-45.8%	$27.6M+11.6%	$24.7M-17.9%	$30.1M+48.4%	$20.3M	N/A	$12.1M-19.5%	$15.1M+97.4%	$7.6M+73.0%	$4.4M+48.5%	$3.0M
Operating Income	-$2.8M	$3.4M+143.9%	-$7.7M+57.0%	-$17.8M+78.8%	-$84.1M+49.6%	-$166.8M-61.0%	-$103.6M-96.5%	-$52.7M	N/A	N/A	-$34.6M+17.6%	-$42.0M-338.4%	-$9.6M+33.5%	-$14.4M
EBITDA	N/A	$3.9M+155.4%	-$7.0M+59.5%	-$17.4M+79.1%	-$83.1M+49.9%	-$165.8M-60.4%	-$103.3M-96.9%	-$52.5M	N/A	N/A	-$34.6M+17.7%	-$42.0M-338.6%	-$9.6M+33.3%	-$14.4M
Interest Expense	$2.4M	$2.4M+5.5%	$2.2M-1.2%	$2.3M+4.3%	$2.2M-18.3%	$2.7M+29.3%	$2.1M	$0	N/A	N/A	$1.0M-8.7%	$1.1M+202.5%	$375K+559.9%	$57K
Income Tax	N/A	$2K	N/A	$17K-61.4%	$44K+158.8%	$17K+325.0%	$4K0.0%	$4K+100.0%	$2K-33.3%	$3K+100.5%	-$613K	$0	$0	N/A
Net Income	-$15.3M	$391K+104.4%	-$8.9M-116.7%	$53.0M+169.1%	-$76.7M+62.6%	-$205.2M-44.2%	-$142.3M-77.8%	-$80.0M	N/A	N/A	-$66.7M-54.5%	-$43.2M-298.9%	-$10.8M+27.9%	-$15.0M
EPS (Basic)	N/A	$0.00+100.0%	-$0.11-101.1%	$10.36+106.2%	-$167.42-608.5%	-$23.63-1014.6%	-$2.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.11	$0.00+100.0%	-$0.11	$0.05	-$167.42	-$23.63	-$2.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	6.42B+7926.9%	80M	984M	465,967	9M	67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$2.6M-45.4%	$899K+6.4%	$9.6M+34.6%	$5.0M+10.1%	$4.8M+16.0%	$845K-76.5%	$7.1M+46.8%	$4.5M-12.1%
Cost of Revenue	$511K-32.3%	$410K+12.3%	$2.6M+71.4%	$905K+4.1%	$755K-1.8%	$365K-46.6%	$1.5M+58.5%	$869K-54.0%
Gross Profit	$2.1M-47.9%	$489K+1.9%	$7.0M+24.6%	$4.0M+11.6%	$4.1M+20.0%	$480K-83.6%	$5.6M+43.9%	$3.6M+12.5%
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	$649K-53.1%	$332K-45.9%
SG&A Expenses	$1.8M-0.8%	$2.4M+0.3%	$1.1M-67.9%	$2.1M-31.6%	$1.8M-18.7%	$2.4M-16.3%	$3.4M+5.2%	$3.1M-3.9%
Operating Income	-$2.5M-99.0%	-$4.6M-1497.2%	$3.3M+433.5%	$951K+139.0%	-$1.3M+9.9%	$327K+111.5%	-$1.0M+70.3%	-$2.4M+31.3%
EBITDA	-$2.5M-116.8%	-$4.5M-907.6%	$3.4M+605.7%	$1.0M+148.5%	-$1.1M+17.5%	$556K+119.6%	-$680K+82.3%	-$2.1M+30.1%
Interest Expense	$600K+2.0%	$614K+6.4%	$602K+4.3%	$599K+7.7%	$588K+7.7%	$577K+2.3%	$577K+1.1%	$556K-1.9%
Income Tax	N/A	-$1K	N/A	-$4K+50.0%	$7K-12.5%	N/A	N/A	-$8K-172.7%
Net Income	-$11.0M-518.6%	-$5.5M-671.7%	$2.8M+191.8%	-$1.6M+33.7%	-$1.8M-232.1%	$956K+119.9%	-$3.0M-43.7%	-$2.4M-103.6%
EPS (Basic)	-$0.08-700.0%	-$0.04-500.0%	$0.02+200.0%	-$0.01+50.0%	-$0.01-150.0%	$0.01+106.3%	-$0.02+99.8%	-$0.02-100.1%
EPS (Diluted)	-$0.08-700.0%	-$0.04	$0.02+200.0%	-$0.01+50.0%	-$0.01	$0.00+100.0%	-$0.02	-$0.02
Diluted Shares (Avg)	137M+14.0%	133M-97.8%	N/A	120M+24.0%	120M-92.5%	6.16B+19631.2%	N/A	96M

EVFM Balance Sheet

EVFM quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$20.3M-14.8%	$23.8M+125.4%	$10.6M-58.1%	$25.2M-40.8%	$42.5M-61.3%	$110.0M+288.6%	$28.3M+605.6%	$4.0M+1.5%	$4.0M-72.5%	$14.4M-64.2%	$40.1M-47.8%	$76.9M	N/A
Current Assets	$15.3M+12.3%	$13.6M+47.8%	$9.2M-27.5%	$12.7M-57.9%	$30.1M-69.2%	$97.7M+269.9%	$26.4M+966.2%	$2.5M+5.3%	$2.4M-80.8%	$12.3M-69.1%	$39.7M-48.3%	$76.9M	N/A
Cash & Equivalents	$578K-22.0%	$741K+27.8%	$580K-79.1%	$2.8M-64.2%	$7.7M-84.2%	$48.9M+214.0%	$15.6M+1070.8%	$1.3M+9.8%	$1.2M-89.4%	$11.5M-69.6%	$37.7M-50.3%	$75.9M+1640.3%	$4.4M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$1.1M-28.4%	$1.6M-7.1%	$1.7M-68.5%	$5.4M-29.9%	$7.7M+7.1%	$7.2M	$0	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$12.5M+26.9%	$9.8M+71.3%	$5.7M+409.6%	$1.1M-82.5%	$6.4M+504.4%	$1.1M	$0	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$94.6M-0.5%	$95.0M+23.3%	$77.1M-20.5%	$97.0M-31.8%	$142.1M+30.8%	$108.6M+758.1%	$12.7M-53.7%	$27.4M-90.7%	$293.5M+50.2%	$195.5M+22.3%	$159.8M+1271.7%	$11.7M	N/A
Current Liabilities	$84.8M+5.4%	$80.4M+11.0%	$72.5M-22.8%	$93.8M-31.8%	$137.7M+78.1%	$77.3M+510.5%	$12.7M-53.7%	$27.3M-73.6%	$103.3M+508.0%	$17.0M+86.8%	$9.1M+376.5%	$1.9M	N/A
Non-Current Liabilities	$9.8M-32.9%	$14.6M+217.3%	$4.6M+46.9%	$3.1M-29.2%	$4.4M-85.9%	$31.3M	$0-100.0%	$37K-100.0%	$190.2M+6.6%	$178.5M+18.4%	$150.7M+1447.2%	$9.7M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$7.2M-26.0%	$9.7M	N/A
Total Equity	-$74.3M-4.3%	-$71.3M-7.1%	-$66.5M+7.4%	-$71.8M+31.2%	-$104.3M-7844.2%	$1.3M-91.4%	$15.6M+166.9%	-$23.4M+91.9%	-$289.5M-59.9%	-$181.1M-51.3%	-$119.7M-283.5%	$65.2M+215.1%	-$56.7M
Retained Earnings	-$897.4M0.0%	-$897.7M-1.0%	-$888.7M+5.3%	-$938.7M-9.1%	-$860.7M-31.3%	-$655.5M-27.7%	-$513.2M-18.5%	-$433.1M-41.0%	-$307.3M-52.1%	-$202.0M-79.0%	-$112.8M-61.9%	-$69.7M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$7.5M-47.7%	$7.4M-42.2%	$20.3M-14.8%	$13.8M-42.3%	$14.4M+68.2%	$12.9M+56.7%	$23.8M+125.4%	$23.9M+79.7%
Current Assets	$6.1M-32.2%	$6.1M+3.1%	$15.3M+12.3%	$7.9M-7.7%	$9.0M+24.3%	$5.9M-15.2%	$13.6M+47.8%	$8.6M-25.4%
Cash & Equivalents	$285K-61.9%	$1.5M+574.7%	$578K-22.0%	$840K+16.3%	$748K+8.1%	$221K-67.9%	$741K+27.8%	$722K+76.1%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$2.2M+13.1%	$1.9M-16.5%	$1.1M-28.4%	$1.7M+15.1%	$1.9M+79.8%	$2.3M+73.3%	$1.6M-7.1%	$1.5M-42.1%
Accounts Receivable	$2.5M-49.4%	$560K-51.3%	$12.5M+26.9%	$4.4M-17.8%	$4.9M+6.9%	$1.1M-73.3%	$9.8M+71.3%	$5.4M-14.7%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$95.0M+13.1%	$85.1M+3.2%	$94.6M-0.5%	$88.9M-1.3%	$84.0M+7.9%	$82.5M+4.5%	$95.0M+23.3%	$90.1M+32.7%
Current Liabilities	$88.6M+19.9%	$78.8M+11.1%	$84.8M+5.4%	$78.2M+2.5%	$73.9M+1.0%	$70.9M-4.6%	$80.4M+11.0%	$76.3M+12.4%
Non-Current Liabilities	$6.4M-36.4%	$6.3M-45.6%	$9.8M-32.9%	$10.7M-22.5%	$10.1M+115.6%	$11.6M+150.0%	$14.6M+217.3%	$13.8M+105938.5%
Total Equity	-$87.5M-25.7%	-$77.6M-11.6%	-$74.3M-4.3%	-$75.1M-5.9%	-$69.6M-0.4%	-$69.6M+1.5%	-$71.3M-7.1%	-$70.9M-25.8%
Retained Earnings	-$914.0M-1.7%	-$902.9M-0.7%	-$897.4M0.0%	-$900.2M-0.6%	-$898.5M-0.7%	-$896.7M-0.4%	-$897.7M-1.0%	-$894.6M-1.1%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

EVFM Cash Flow Statement

EVFM quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$472K	-$2.0M+48.7%	-$3.9M+56.7%	-$9.0M+87.3%	-$70.4M+52.0%	-$146.7M-39.9%	-$104.8M-90.3%	-$55.1M	N/A	-$19.2M+21.2%	-$24.4M+35.6%	-$37.9M-296.1%	-$9.6M+25.8%	-$12.9M
Depreciation & Amortization	N/A	$518K-20.2%	$649K+36.1%	$477K-53.0%	$1.0M-0.8%	$1.0M+238.7%	$302K+14.8%	$263K+0.4%	$262K+7.4%	$244K+165.2%	$92K+57.5%	$58K+230.7%	$18K-75.5%	$72K
Stock-Based Compensation	N/A	$166K-80.4%	$847K-28.8%	$1.2M-64.1%	$3.3M-62.8%	$8.9M-29.9%	$12.7M+48.0%	$8.6M-51.9%	$17.8M+1972.2%	$861K-39.8%	$1.4M-9.3%	$1.6M+157.5%	$613K+661.6%	$80K
Capital Expenditures	$5K	$5K-64.3%	$14K+250.0%	$4K-98.8%	$341K-88.4%	$2.9M+30.4%	$2.3M+1274.4%	$164K+2242.9%	$7K+16.7%	$6K-98.8%	$498K+120.2%	$226K+1150.8%	$18K-14.6%	$21K
Free Cash Flow	-$477K	-$2.0M+48.8%	-$3.9M+56.5%	-$9.0M+87.3%	-$70.8M+52.7%	-$149.6M-39.7%	-$107.1M-93.8%	-$55.3M	N/A	-$19.2M+22.7%	-$24.9M+34.7%	-$38.1M-297.7%	-$9.6M+25.8%	-$12.9M
Investing Cash Flow	-$5K	-$62K+89.1%	-$569K-14125.0%	-$4K+98.8%	-$341K+87.3%	-$2.7M-143.2%	$6.2M+176.8%	-$8.1M-478.7%	$2.1M	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$14K	$1.9M-59.0%	$4.6M-3.4%	$4.8M-92.3%	$61.9M-31.7%	$90.7M-41.2%	$154.2M+97.5%	$78.1M	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$200K	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$18K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$3.1M-7.6%	$2.3M+310.9%	$31K+101.3%	$336K+173.2%	-$2.9M-155.8%	$560K+355.3%	-$2.4M-1316.5%	-$459K+80.6%
Depreciation & Amortization	$18K-83.8%	$79K-65.5%	$94K-70.9%	$84K-72.6%	$111K+1485.7%	$229K+1808.3%	$323K+169.0%	$307K-38.6%
Stock-Based Compensation	N/A	$15K-78.6%	N/A	$23K-88.7%	$31K-85.8%	$70K-70.5%	N/A	$203K-21.3%
Capital Expenditures	$0	$2K	$3K	$0	N/A	N/A	$0	$0
Free Cash Flow	-$3.1M	$2.3M	$28K+101.2%	$336K+173.2%	N/A	N/A	-$2.4M-1316.5%	-$459K+80.6%
Investing Cash Flow	$0+100.0%	-$2K+96.5%	-$3K+93.5%	$0+100.0%	-$2K	-$57K-307.1%	-$46K	-$509K
Financing Cash Flow	$1.0M-59.1%	-$498K-268.9%	-$290K-111.7%	-$244K-124.4%	$2.6M	-$135K	$2.5M+627.4%	$998K-53.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

EVFM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EVFM quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Gross Margin	77.1%-3.1pp	80.2%+15.9pp	64.3%-9.5pp	73.8%+23.0pp	50.8%+55.7pp	-4.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	16.7%+56.4pp	-39.6%+58.3pp	-98.0%	-499.6%	-2023.3%	-23234.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	1.9%+47.7pp	-45.8%	290.8%	-455.5%	-2489.0%	-31907.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	-10564.9%-10053.0pp	-511.9%	N/A	N/A	N/A	N/A	-16.6%	N/A
Return on Assets	1.9%+39.2pp	-37.2%-539.2pp	502.0%+806.8pp	-304.8%+177.9pp	-482.7%-353.3pp	-129.4%+153.4pp	-282.9%	N/A	N/A	-463.9%-356.3pp	-107.6%-93.5pp	-14.1%	N/A
Current Ratio	0.180.0x	0.170.0x	0.130.0x	0.14-0.1x	0.22-1.0x	1.26-0.8x	2.09+2.0x	0.09+0.1x	0.02-0.7x	0.72-3.6x	4.37-35.9x	40.26	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	80.64+79.8x	0.81	N/A	N/A	N/A	N/A	0.15	N/A
Asset Turnover	1.00+0.2x	0.81-0.9x	1.73+1.1x	0.67+0.5x	0.19+0.2x	0.000.0x	0.00	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	-9.9%+10.3pp	-20.1%+29.1pp	-49.3%	-420.2%	-1814.7%	-24009.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	80.6%-3.8pp	54.4%-2.4pp	72.9%-5.8pp	81.7%+1.1pp	84.4%+2.8pp	56.8%-24.2pp	78.7%-1.6pp	80.7%+17.6pp
Operating Margin	-94.5%-68.6pp	-508.2%	35.0%+49.1pp	19.2%+73.5pp	-25.9%+7.5pp	38.7%+117.6pp	-14.1%+55.7pp	-54.3%+15.2pp
Net Margin	-419.1%	-607.9%	29.2%+71.9pp	-31.7%+20.9pp	-37.0%-69.4pp	113.1%	-42.8%+0.9pp	-52.6%
Return on Assets	-146.7%-134.3pp	-73.4%-80.8pp	13.8%+26.5pp	-11.4%-1.5pp	-12.4%-28.2pp	7.4%+66.0pp	-12.8%+7.3pp	-9.9%-505.3pp
Current Ratio	0.07-0.1x	0.080.0x	0.180.0x	0.100.0x	0.120.0x	0.080.0x	0.170.0x	0.11-0.1x
Asset Turnover	0.350.0x	0.12+0.1x	0.47+0.2x	0.36+0.2x	0.34-0.2x	0.07-0.4x	0.30-0.2x	0.19-0.2x
FCF Margin	-119.3%	255.7%	0.3%+34.2pp	6.8%+17.0pp	N/A	N/A	-33.9%-30.4pp	-10.2%+36.0pp

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$74.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.18), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
EVOFEM BIOSCIENCE INC EVFM	FY2025	$20.2M	$391K	1.9%	$1.0M	—
REGEN BIOPHARMA PFD A RGBPP	FY2025	$237K	-$1.3M	N/A	N/A	—
OCEAN BIOMEDICAL INC OCEA	FY2024	N/A	N/A	N/A	$6.8M	—

Where EVOFEM BIOSCIENCE INC Ranks

Frequently Asked Questions

What is EVOFEM BIOSCIENCE INC's annual revenue?

EVOFEM BIOSCIENCE INC (EVFM) reported $20.2M in total revenue for fiscal year 2025. This represents a 4.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is EVOFEM BIOSCIENCE INC's revenue growing?

EVOFEM BIOSCIENCE INC (EVFM) revenue grew by 4.2% year-over-year, from $19.4M to $20.2M in fiscal year 2025.

Is EVOFEM BIOSCIENCE INC profitable?

Yes, EVOFEM BIOSCIENCE INC (EVFM) reported a net income of $391K in fiscal year 2025, with a net profit margin of 1.9%.

What is EVOFEM BIOSCIENCE INC's EBITDA?

EVOFEM BIOSCIENCE INC (EVFM) had EBITDA of $3.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is EVOFEM BIOSCIENCE INC's gross margin?

EVOFEM BIOSCIENCE INC (EVFM) had a gross margin of 77.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is EVOFEM BIOSCIENCE INC's operating margin?

EVOFEM BIOSCIENCE INC (EVFM) had an operating margin of 16.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is EVOFEM BIOSCIENCE INC's net profit margin?

EVOFEM BIOSCIENCE INC (EVFM) had a net profit margin of 1.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is EVOFEM BIOSCIENCE INC's free cash flow?

EVOFEM BIOSCIENCE INC (EVFM) recorded an outflow of $2.0M in free cash flow during fiscal year 2025. This represents a 48.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is EVOFEM BIOSCIENCE INC's operating cash flow?

EVOFEM BIOSCIENCE INC (EVFM) recorded an outflow of $2.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are EVOFEM BIOSCIENCE INC's total assets?

EVOFEM BIOSCIENCE INC (EVFM) had $20.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are EVOFEM BIOSCIENCE INC's capital expenditures?

EVOFEM BIOSCIENCE INC (EVFM) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does EVOFEM BIOSCIENCE INC have outstanding?

EVOFEM BIOSCIENCE INC (EVFM) had 133M shares outstanding as of fiscal year 2025.

What is EVOFEM BIOSCIENCE INC's current ratio?

EVOFEM BIOSCIENCE INC (EVFM) had a current ratio of 0.18 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is EVOFEM BIOSCIENCE INC's return on assets (ROA)?

EVOFEM BIOSCIENCE INC (EVFM) had a return on assets of 1.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is EVOFEM BIOSCIENCE INC's P/E ratio?

EVOFEM BIOSCIENCE INC (EVFM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.0M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is EVOFEM BIOSCIENCE INC's price-to-sales ratio?

EVOFEM BIOSCIENCE INC (EVFM) trades at 0.1x sales, its market capitalization divided by revenue of $18.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.0M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does EVOFEM BIOSCIENCE INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, EVOFEM BIOSCIENCE INC (EVFM) held $578K in cash, cash equivalents and investments, and reported an operating cash outflow of $2.0M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is EVOFEM BIOSCIENCE INC's debt-to-equity ratio negative or not reported?

EVOFEM BIOSCIENCE INC (EVFM) has negative shareholder equity of -$74.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is EVOFEM BIOSCIENCE INC's Altman Z-Score?

EVOFEM BIOSCIENCE INC (EVFM) has an Altman Z-Score of -64.53, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is EVOFEM BIOSCIENCE INC's Piotroski F-Score?

EVOFEM BIOSCIENCE INC (EVFM) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are EVOFEM BIOSCIENCE INC's earnings high quality?

For every $1 of reported earnings, EVOFEM BIOSCIENCE INC (EVFM) used $5.09 of operating cash (-$2.0M OCF vs $391K net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can EVOFEM BIOSCIENCE INC cover its interest payments?

EVOFEM BIOSCIENCE INC (EVFM) has an interest coverage ratio of 1.43x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.